Event-Driven Stocks

AVENUE THERAPEUTICS, INC.

ATXIOTC

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 3 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$1.4M$0————
Operating income−$3.1M−$11.3M−$14.5M−$8.0M−$3.7M−$5.2M
Net income−$2.9M−$11.7M−$10.5M−$3.6M−$3.7M−$5.2M
Total assets$2.9M$2.7M$1.9M$6.8M$4.0M$3.2M
Total liabilities$1.1M$816,000$1.2M$3.6M$509,000$886,000
Equity$1.8M$2.8M$1.6M$3.9M$3.5M$2.4M
EPS (diluted)$-0.93$-15.79$-73.48$-1.63$-0.22$-0.31
Shares out.3.1M44.3M5.9M21.7M16.7M16.7M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−219.6%
Net margin
−207.2%
Return on equity
−158.8%
Return on assets
−99.2%
Return on capital (ROCE)
−168.3%
Liabilities / assets
37.5%
Debt / equity
0.60×
Book value / share
$0.58
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
−36.7%clean
Piotroski F-Score
4/7mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
59
/ 100
Profitability 0Growth n/aCatalyst 67Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 3 warning● 2 good
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202611.0-100.0%
Apr 30, 20266,5111.0+154.3%
Apr 15, 20262,5601.0-51.6%
Mar 31, 20265,2901.0+735.7%
Mar 13, 20266331.0-88.0%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.